Some of biopharma’s biggest assets face a solo existence

A clinical trial using a statistical method that had prompted some criticism has catapulted Allakos and its lead asset, lirentelimab, to the top of a ranking of biotech assets that have yet to attract a significant partner, EvaluatePharma data show.